By Professor David Goldstein

Journal articles

Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2020, 'Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis', British Journal of Cancer, 122, pp. 1486 - 1495, http://dx.doi.org/10.1038/s41416-020-0782-1

Oar A; Lee M; Le H; Hruby G; Dalfsen R; Pryor D; Lee D; Chu J; Holloway L; Briggs A; Barbour A; Chander S; Ng SP; Samra J; Shakeshaft J; Goldstein D; Nguyen N; Goodman KA; Chang DT; Kneebone A, 2020, 'Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT)', Practical Radiation Oncology, 10, pp. e136 - e146, http://dx.doi.org/10.1016/j.prro.2019.07.018

Kokkinos J; Ignacio RMC; Sharbeen G; Boyer C; Gonzales-Aloy E; Goldstein D; McCarroll JA; Phillips PA, 2020, 'Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs', Biomaterials, 240, http://dx.doi.org/10.1016/j.biomaterials.2019.119742

Sahai V; Tabernero J; Van Cutsem E; Reni M; Tempero MA; O'Reilly EM; Berlin J; Riess H; Goldstein D; Li M; Lu B; Ferrara S; Philip PA, 2020, 'Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT): Recurrence patterns.', Journal of Clinical Oncology, 38, pp. 704 - 704, http://dx.doi.org/10.1200/jco.2020.38.4_suppl.704

Best MC; Butow P; Jacobs C; Savard J; Biesecker B; Ballinger ML; Bartley N; Davies G; Napier CE; Smit AK; Thomas DM; Newson AJ, 2020, 'Who should access germline genome sequencing? A mixed methods study of patient views', Clinical Genetics, 97, pp. 329 - 337, http://dx.doi.org/10.1111/cge.13664

Tjokrowidjaja A; Goldstein D; Hudson HM; Lord SJ; Gebski V; Clarke S; de Souza P; Motzer RJ; Lee CK, 2020, 'The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy', Acta Oncologica, 59, pp. 20 - 27, http://dx.doi.org/10.1080/0284186X.2019.1656342

Timmins HC; Li T; Kiernan MC; Horvath LG; Goldstein D; Park SB, 2020, 'Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients', Journal of Pain, 21, pp. 44 - 58, http://dx.doi.org/10.1016/j.jpain.2019.06.011

Wang X; Yeo RX; Hogg PJ; Goldstein D; Crowe P; Dilda PJ; Yang JL, 2020, 'The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas', Oncotarget, 11, pp. 46 - 61, http://dx.doi.org/10.18632/oncotarget.27416

Perera C; Xu Z; Mekapogu AR; Hosen SMZ; Pothula S; Greenfield J; Chari S; Goldstein D; Pirola R; Wilson J; Apte MV, 2020, '1133 PANCREATIC STELLATE CELL AND CANCER CELL DERIVED EXOSOMES IMPAIR BETA CELL FUNCTION: IMPLICATIONS FOR PANCREATIC CANCER RELATED DIABETES.', Gastroenterology, 158, pp. S - 221, http://dx.doi.org/10.1016/s0016-5085(20)31245-2

Li T; Timmins HC; McCrary JM; Trinh T; Horvath LG; Friedlander ML; Kiernan MC; Goldstein D; Park SB, 2020, '5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients', Clinical Neurophysiology, 131, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2019.11.038

Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Marx G; Boyle F; Goldstein D; Park SB, 2020, '8. Electrophysiological and phenotypic profiles of taxane-induced neuropathy', Clinical Neurophysiology, 131, pp. e4 - e4, http://dx.doi.org/10.1016/j.clinph.2019.11.041

Kokkinos J; Sharbeen G; Haghighi K; Ignacio RM; Kopecky C; Gonzales-Aloy E; Youkhana J; Pandzic E; Boyer C; Davis T; Butler L; Goldstein D; McCarroll J; Phillips P, 2020, 'Bringing the pancreas patient back to the bench: Ex vivo culture of intact human patient derived pancreatic tumour tissue', , http://dx.doi.org/10.1101/2020.07.30.223925

Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D, 2019, 'Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade', Supportive Care in Cancer, 27, pp. 4771 - 4777, http://dx.doi.org/10.1007/s00520-019-04781-6

McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Friedlander M; Bosco A; Harrison M; Maier N; O'Neill S; Park SB, 2019, 'Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy', Journal of Pain and Symptom Management, 58, pp. 1023 - 1032, http://dx.doi.org/10.1016/j.jpainsymman.2019.07.021

Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B, 2019, 'Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer', Oncologist, 24, pp. e1102 - e1107, http://dx.doi.org/10.1634/theoncologist.2018-0613

Tang M; Chen J; Goldstein D; Links M; Lord S; Marschner I; Simes RJ; Lee CK, 2019, 'Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer', Pancreas, 48, pp. 1274 - 1284, http://dx.doi.org/10.1097/MPA.0000000000001429

Li T; Timmins H; King T; Kiernan M; Goldstein D; Park S, 2019, 'Bortezomib Induced Peripheral Neuropathy: A Systematic Review of Phase III Trials', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19, pp. E346 - E346, http://dx.doi.org/10.1016/j.clml.2019.09.571

McCrary JM; Goldstein D; Sandler CX; Barry BK; Marthick M; Timmins HC; Li T; Horvath L; Grimison P; Park SB, 2019, 'Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 27, pp. 3849 - 3857, http://dx.doi.org/10.1007/s00520-019-04680-w

McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; Andre T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater JA; Valle JW, 2019, 'Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial', ANNALS OF ONCOLOGY, 30, pp. 274 - 274, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295502144&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P, 2019, 'Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer', Annals of Oncology, 30, pp. 1472 - 1478, http://dx.doi.org/10.1093/annonc/mdz200

Maharaj AD; Holland JF; Scarborough RO; Evans SM; Ioannou LJ; Brown W; Croagh DG; Pilgrim CHC; Kench JG; Lipton LR; Leong T; McNeil JJ; Nikfarjam M; Aly A; Burton PR; Cashin PA; Chu J; Duong CP; Evans P; Goldstein D; Haydon A; Hii MW; Knowles BPF; Merrett ND; Michael M; Neale RE; Philip J; Porter IWT; Smith M; Spillane J; Tagkalidis PP; Zalcberg JR, 2019, 'The Upper Gastrointestinal Cancer Registry (UGICR): A clinical quality registry to monitor and improve care in upper gastrointestinal cancers', BMJ Open, 9, pp. e031434, http://dx.doi.org/10.1136/bmjopen-2019-031434

McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB, 2019, 'Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test', Journal of Cancer Survivorship, 13, pp. 495 - 502, http://dx.doi.org/10.1007/s11764-019-00769-7

Best MC; Bartley N; Jacobs C; Juraskova I; Goldstein D; Newson AJ; Savard J; Meiser B; Ballinger M; Napier C; Thomas D; Biesecker B; Butow P; Tucker K; Schlub T; Vines R; Vines K; Kirk J; Young MA, 2019, 'Patient perspectives on molecular tumor profiling: "why wouldn't you?"', BMC Cancer, 19, pp. 753, http://dx.doi.org/10.1186/s12885-019-5920-x

Reni M; Riess H; O'Reilly E; Santoro A; Park J; Bekaii-Saab T; Tempero M; Shan Y; Macarulla T; Van Cutsem E; Noel M; Berlin J; Biankin A; Dhani N; Frassineti G; Goldstein D; Romano A; Bruchec YL; Philip P, 2019, 'An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes', Annals of oncology : official journal of the European Society for Medical Oncology, 30, pp. iv126, http://dx.doi.org/10.1093/annonc/mdz154

Reni M; Winter J; Tortora G; Pelzer U; Riess H; Chang H; O'Reilly E; Oh D; Diaz IA; Milella M; Bendell J; Garlipp B; Tempero M; Macarulla T; Van Cutsem E; Berlin J; Goldstein D; Lu B; Jeanes J; Philip P, 2019, 'Analysis of patient screening in the phase III, international, randomized, open-label APACT trial', Annals of oncology : official journal of the European Society for Medical Oncology, 30, pp. iv110, http://dx.doi.org/10.1093/annonc/mdz156

Tempero MA; Reni M; Riess H; Pelzer U; O'Reilly EM; Winter JM; Oh D-Y; Li C-P; Tortora G; Chang H-M; Lopez CD; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Ferrara S; Li M; Lu BD; Biankin A, 2019, 'APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.', Journal of Clinical Oncology, 37, pp. 4000 - 4000, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4000

Thavaneswaran S; Napier C; Goldstein D; Meiser B; Butow P; Thomas DM; Ballinger ML; Best M, 2019, 'Medical oncologists’ experience with returning molecular tumor profiling to patients.', Journal of Clinical Oncology, 37, pp. 10521 - 10521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10521

Knox JJ; McNamara MG; Palmer DH; Evans TRJ; Goldstein D; Bridgewater JA; Valle JW, 2019, 'NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.', Journal of Clinical Oncology, 37, pp. TPS4156 - TPS4156, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps4156

Michael M; Wong R; Gill SS; Goldstein D; Ngan S; Heriot AG; Link E; Farrell M; Neeson PJ; Ramsay RG; Wilson K; Mitchell C; Tie J; Pavlakis N; Zalcberg JR; Segelov E, 2019, 'Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.TPS3622

Lim BT; Butow P; Mills J; Miller A; Pearce A; Goldstein D, 2019, 'Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings', Journal of Psychosocial Oncology, 37, pp. 383 - 397, http://dx.doi.org/10.1080/07347332.2018.1551261

Kaur R; Meiser B; Zilliacus E; Tim Wong WK; Woodland L; Watts K; Tomkins S; Kissane D; Girgis A; Butow P; Hale S; Perry A; Aranda SK; Shaw T; Tebble H; Norris C; Goldstein D, 2019, 'Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds', Supportive Care in Cancer, 27, pp. 1951 - 1960, http://dx.doi.org/10.1007/s00520-018-4507-4

Sonbol MB; Ahn DH; Goldstein D; Okusaka T; Tabernero J; Macarulla T; Reni M; Li CP; O'Neil B; Van Cutsem E; Bekaii-Saab T, 2019, 'CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine', Future Oncology, 15, pp. 1295 - 1302, http://dx.doi.org/10.2217/fon-2018-0903

Maharaj AD; Ioannou L; Croagh D; Zalcberg J; Neale RE; Goldstein D; Merrett N; Kench JG; White K; Pilgrim CHC; Chantrill L; Cosman P; Kneebone A; Lipton L; Nikfarjam M; Philip J; Sandroussi C; Tagkalidis P; Chye R; Haghighi KS; Samra J; Evans SM, 2019, 'Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus', HPB, 21, pp. 444 - 455, http://dx.doi.org/10.1016/j.hpb.2018.08.016

Sclafani F; Hesselberg G; Thompson SR; Truskett P; Haghighi K; Rao S; Goldstein D, 2019, 'Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review', Journal of Surgical Oncology, 119, pp. 489 - 496, http://dx.doi.org/10.1002/jso.25320

Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP, 2019, 'The Impact of Positive Resection Margins on Survival and Recurrence following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma', Annals of Surgery, 269, pp. 520 - 529, http://dx.doi.org/10.1097/SLA.0000000000002557

Livni L; Lees JG; Barkl-Luke ME; Goldstein D; Moalem-Taylor G, 2019, 'Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture', Neuroscience Letters, 694, pp. 14 - 19, http://dx.doi.org/10.1016/j.neulet.2018.11.016

McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB, 2019, 'Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments', JNCCN Journal of the National Comprehensive Cancer Network, 17, pp. 949 - 955, http://dx.doi.org/10.6004/jnccn.2019.7290

Oxford LE; Urken M; Lazarus C; Cheney J; Scharpf J; Fritz MA; Puscas L; Mlynarek AM; Sela E; Ibrahim B; Hier MP; Hanasono MM; Yu P; Hornig JD; Miles B; Teng M; Genden E; Patel UA; Lin AC; Malone JP; Rosenthal EL; Clemons L; Zhang H; O'Connell DA; Ansari K; Harris JR; Seikaly H; Moreno MA; Luu Q; Jacobson J; Farwell DG; Blackwell K; Zaghi S; Nabili V; Wang SJ; Burgess BC; Casper K; Goddard J; Bayon R; Pagedar NA; Chang KE; Hoffman HT; Shnayder Y; Bond J; Sykes KJ; Girod DA; Tsue TT; Gal TJ; Way TJ; Leibowitz JM; Mantravadi AV; Grobman AB; Weed DT; Civantos F; Chepeha DB; Rosko A; Belile E; Chanowski EJP; Wolf GT; Bradford CR; Prince ME; Moyer JS; Spector ME; Khariwala SS; Lassig AA; Jorgensen JB; Showmaker J; Umstattd LA; Lai E; Zitsch RP; Renner GJ; Militsakh O; Flohr J; van der Sloot P; Miller M; Myers LL; Sumer BD; Truelson JM; Goldstein D; Cohen M; Gilbert R; Irish J; Gullane P; Brown D; Buchmann L; Hunt J; Jameson MJ; Shonka DC; Futran ND; Mendez E; Fung K; Belzile M; Dowthwaite SA; Yoo JH; Nichols AC; Franklin JH; Nussenbaum B; Desai S; Diaz J, 2019, 'Salvage laryngectomy and laryngopharyngectomy: Multicenter review of outcomes associated with a reconstructive approach', Head and Neck, 41, pp. 16 - 29, http://dx.doi.org/10.1002/hed.25192

Tempero MA; Reni M; Riess H; O’Reilly EM; Krishnamurthi S; Österlund P; Ales-Diaz IC; Milella M; Siena S; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin JD; Li M; Ferrara S; Bruchec YL; McGovern D; Biankin A, 2019, 'Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses', Annals of Oncology, 30, pp. v259 - v260, http://dx.doi.org/10.1093/annonc/mdz247.010

Chua YJ; Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Bang Y-J; Alcindor T; O’callaghan CJ; Bekaii-Saab TS; Grothey A; Chen L-T; Simes J; Zalcberg JR; Goldstein D; Komatsu Y; Machida N; Esaki T; Hara H; Shitara K, 2019, 'Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II', Annals of Oncology, 30, pp. vi137 - vi137, http://dx.doi.org/10.1093/annonc/mdz343.087

Kaur R; Meiser B; Ziliacus E; Wong WKT; Woodland L; Watts K; Tomkins S; Kissane D; Girgis A; Butow P; Hale S; Perry A; Aranda SK; Shaw T; Tebble H; Norris C; Goldstein D, 2018, 'Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds', Supportive Care in Cancer, http://dx.doi.org/10.1007/s00520-018-4507-4

Beesley VL; Janda M; Burmeister EA; Goldstein D; Gooden H; Merrett ND; O'Connell DL; Wyld DK; Chan RJ; Young JM; Neale RE, 2018, 'Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes', Palliative and Supportive Care, 16, pp. 534 - 543, http://dx.doi.org/10.1017/S1478951517000608

Tan SYS; O’Neill S; Goldstein D; Ward RL; Daniels B; Vajdic CM, 2018, 'Predictors of care for patients with cancer of unknown primary site in three Australian hospitals', Asia-Pacific Journal of Clinical Oncology, 14, pp. e512 - e520, http://dx.doi.org/10.1111/ajco.12815

Thompson SR; Lee ISY; Carroll S; Bishop S; Douglas P; Lam F; Brown C; Williams J; Goldstein D, 2018, 'Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?', ANZ Journal of Surgery, 88, pp. 870 - 875, http://dx.doi.org/10.1111/ans.14398

Dumbrava MI; Burmeister EA; Wyld D; Goldstein D; O'Connell DL; Beesley VL; Gooden HM; Janda M; Jordan SJ; Merrett ND; Payne ME; Waterhouse MA; Neale RE, 2018, 'Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival', Asia-Pacific Journal of Clinical Oncology, 14, pp. 326 - 336, http://dx.doi.org/10.1111/ajco.12862

Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS; Lerzo G; O'Connor JM; Mendez GA; Lynam J; Tebbutt N; Wong M; Strickland A; Karapetis C; Goldstein D; Vasey P; Van Laethem JL; Van Cutsem E; Berry S; Vincent M; Muller B; Rey F; Zambrano A; Guerra J; Krogh M; Baeksgaard L; Yilmaz M; Elme A; Magi A; Auvinen P; Alanko T; Moehler M; Kunzmann V; Seufferlein T; Thuss-Patience P; Hoehler T; Haag G; Al-Batran SE; Castro H; Lopez K; Aguilar Vasquez M; Sandoval M; Lam KO; Cuffe S; Kelly C; Geva R; Hubert A; Beny A; Brenner B; Giuseppe A; Falcone A; Maiello E; Passalacqua R; Montesarchio V; Hara H; Chin K; Nishina T; Komatsu Y; Machida N; Hironaka S; Satoh T; Tamura T; Sugimoto N; Cho H; Omuro Y; Kato K; Goto M; Hyodo I; Yoshida K; Baba H; Esaki T; Furuse J; Wan Mohammed WZ; Hernandez Hernandez C; Casas Garcia J; Dominguez Andrade A; Clarke K; Hjortland G; Glenjen N; Kubiatowski T; Jacek J; Wojtukiewicz M; Lazarev S; Lancukhay Y, 2018, 'Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial', The Lancet, 392, pp. 123 - 133, http://dx.doi.org/10.1016/S0140-6736(18)31257-1

Battaglini E; Park SB; Barnes EH; Goldstein D, 2018, 'A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy', Contemporary Clinical Trials, 70, pp. 135 - 138, http://dx.doi.org/10.1016/j.cct.2018.04.011

Wang X; Goldstein D; Crowe PJ; Yang JL, 2018, 'Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines', International Journal of Oncology, 52, pp. 2143 - 2154, http://dx.doi.org/10.3892/ijo.2018.4337

Bekaii-Saab T; Okusaka T; Goldstein D; O'Neill B; Tabernero J; Li C; Reni M; Jin B; Oh C; Borodyansky L; Van Cutsem E, 2018, 'CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress', Annals of oncology : official journal of the European Society for Medical Oncology, 29, pp. v51 - v52, http://dx.doi.org/10.1093/annonc/mdy151.183

Chiorean EG; Von Hoff D; Wan Y; Margunato-Debay S; Botteman M; Goldstein D, 2018, 'Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer', Cancer Management and Research, 10, pp. 1389 - 1396, http://dx.doi.org/10.2147/CMAR.S163475

Back to profile page